drugset
drugset / Trial / NCT07437404

Efficacy and Safety Evaluation Study of SCT800 in Previously Untreated Hemophilia A Patients.

NCT07437404 ↗

Phase 3 Recruiting 36 enrolled Sinocelltech Ltd.
NaSingle-groupOpen-labelPrevention

Summary

This is an Open Label, Uncontrolled Study to Evaluate the the Safety and Efficacy of SCT800 for Prophylaxis Treatment in Severe Previously Untreated Hemophilia Patients.

Timeline

Start
2024-04-26
Primary completion
2028-12-26
Completion
2028-12-26

Drugs

EvaluationDrugModalityDoseRoute
Subject SCT800 Protein / enzyme biologic 10 iu/kg Intravenous
Subject SCT800 Protein / enzyme biologic 15 iu/kg Intravenous
Subject SCT800 Protein / enzyme biologic 20 iu/kg Intravenous
Subject SCT800 Protein / enzyme biologic 30 iu/kg Intravenous
Subject SCT800 Protein / enzyme biologic 50 iu/kg Intravenous

Indications

hemophilia A